Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
10.3971/j.issn.1000-8578.2025.24.1017
- VernacularTitle:血液生物标志物检测对晚期非小细胞肺癌EGFR-TKI治疗疗效的评估价值
- Author:
Rui FAN
1
;
Yonghui WU
1
;
Zhan GU
1
;
Yanbin PENG
1
;
Lixin WANG
1
Author Information
1. Department of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Advanced NSCLC;
EGFR-TKI;
Efficacy;
Circulating tumor cells;
Circulating tumor DNA
- From:
Cancer Research on Prevention and Treatment
2025;52(5):382-387
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. Methods A total of 109 NSCLC patients receiving first-line EGFR-TKI treatment were enrolled. Serum tumor markers CEA, CTCs, and ctDNA were detected at baseline and after one month of treatment. Chest CT scans were performed, and treatment efficacy was evaluated based on RECIST1.1 criteria. CTCs were counted by enrichment-staining-computational algorithm to analyze malignant features, while ctDNA was assessed using digital PCR. Results Survival rate was low in patients with abnormal CEA and ctDNA tests at baseline and in patients with reduced serum CTCs after treatment. In the SD subgroup of patients with brain metastases and advanced stage, the PFS benefit was low. Conclusion Patients in the SD subgroup have significantly higher recurrence risks than those in the PR or CR subgroups. Therefore, CTC and ctDNA testing should be applied to patients in the SD subgroup to identify high-risk patients with poor response to EGFR-TKI treatment, intervene with additional treatment promptly, and obtain long progression-free survival.
